Rallybio Corporation (RLYB) Form 4 Filings

Rallybio Corp director Ronald Hunt exercised options for 14,305 shares of common stock on November 4, 2026, at an exercise price of $4.45 per share. He directly held 29,125 shares of common stock after the transaction. The option was issued under the company's 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees; its vesting was accelerated in full, and it became fully vested and exercisable on October 26, 2026.

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options for 7,124 common shares on November 2, 2026, at an exercise price of $14.88 per share. After the exercise, he directly held 44,139 common shares, and the reported option position was zero. The options were granted under Rallybio's 2021 Equity Incentive Plan.

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options on October 29, 2026, acquiring 7,875 common shares at $14.88 per share and 13,589 common shares at $6.08 per share. The options’ vesting was accelerated in full, and they became fully vested and exercisable on October 26, 2026. No Rule 10b5-1 plan is reported.

Ronald Hunt, a director of Rallybio Corp, exercised options covering 14,820 common shares on October 29, 2026, and acquired the underlying shares. The options had exercise prices of $2.38, $7.60 and $15.28 per share. The option covering 9,196 shares was issued in lieu of $51,500 in retainer fees.

Rallybio Corp (RLYB) director Christine A. Nash exercised 3,562 options on October 28, 2026, at an exercise price of $2.38 per share, acquiring 3,562 common shares. Her reported position after the transaction was 3,562 common shares, and the option position following the transaction was 0. The option was granted under the company's 2021 Equity Incentive Plan.

Rallybio Corp Chief Executive Officer Stephen Uden exercised options on October 27, 2026, to acquire 33,244 common shares at an exercise price of $6.08 per share. His directly held common-stock position after the exercise was 148,864 shares. The reported option balance after the transaction was 0 shares, and the option's expiration date was February 14, 2035.

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber reported acquiring 2,500 shares of common stock on October 26, 2026, followed by a sale of 599 shares on October 27, 2026, at $16.04 per share. The sale occurred upon partial vesting of a performance stock award solely to satisfy tax withholding obligations incurred upon vesting. No Rule 10b5-1 plan was reported.

Rallybio Corp director Wendy Chung exercised options on October 26, 2026, to acquire 2,062 common shares at an exercise price of $15.28 per share. Her direct common-stock holdings after the transaction were 5,624 shares. The option was granted under Rallybio's 2021 Equity Incentive Plan and is listed with an expiration date of May 15, 2034.

Rallybio Corp (RLYB) director Paula Soteropoulos exercised options to acquire 3,562 common shares on October 16, 2026, at an exercise price of $2.38 per share. She directly held 6,544 common shares after the exercise. The option was granted under Rallybio's 2021 Equity Incentive Plan and expires May 13, 2035.

Rallybio Corp (RLYB) director Helen M. Boudreau exercised options to acquire 2,062 common shares at an exercise price of $15.28 per share on October 16, 2026. The reported option position had zero shares remaining after the exercise. Her directly held common-stock position was 8,604 shares afterward.

Rallybio Corp (RLYB) director Robert Lorne Hopfner exercised three options on October 12, 2026, acquiring 14,820 common shares. The options covered 9,196 shares at an exercise price of $7.60 per share, 3,562 at $2.38, and 2,062 at $15.28. All three options were issued or granted under Rallybio’s 2021 Equity Incentive Plan. The 9,196-share option was issued in lieu of $51,500 in retainer fees.

Rallybio Corp (RLYB) reported that Chief Financial Officer Jonathan I. Lieber exercised options on October 9, 2026, acquiring 3,910 common shares at $6.08 per share. His reported common-share holdings following the transaction were 13,650 shares, and the reported option position following the exercise was zero shares. The option was granted under the Company's 2021 Equity Incentive Plan and vests in 48 equal monthly installments, reaching full vesting on February 14, 2029.

Rallybio Corp's Chief Executive Officer, Stephen Uden, exercised options to acquire 22,456 shares of common stock on October 6, 2026, at an exercise price of $6.08 per share. His reported direct common-stock holdings following the transaction were 115,620 shares.

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options covering 5,000 shares on September 29, 2026, at an exercise price of $6.08 per share, and acquired 5,000 common shares. He reported 9,740 directly held common shares following the transaction. The option was granted under Rallybio's 2021 Equity Incentive Plan and vests in 48 equal monthly installments until fully vested on February 14, 2029.

Rallybio Corp (RLYB) director Hui Liu exercised options to acquire 3,562 and 8,482 common shares on September 24, 2026, at exercise prices of $2.38 and $7.60 per share, respectively. The corresponding common-stock entries report acquisition of those same share amounts. The 8,482-share option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $47,500 in retainer fees.

Rallybio Corp (RLYB) director Wendy Chung exercised stock options into common shares. On September 16, 2026, she exercised options for 3,562 shares of common stock at an exercise price of $2.38 per share, converting an option position into directly held stock.

The exercised option for 3,562 underlying shares now shows 0 options remaining from that grant, while her direct ownership in Rallybio common stock is reported as 3,562 shares following the transaction. No Rule 10b5-1 trading plan is reported for this activity.

Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026 at an exercise price of $2.38 per share. Following the transaction, she directly holds 6,542 shares of Common Stock. The options exercised were originally rights to buy Rallybio common stock.

Rallybio Corp disclosed that private investment funds and separately managed accounts managed by ADAR1 Capital Management, LLC made open-market purchases of Rallybio common stock. Across May 18–19, 2026, these ADAR1-managed vehicles bought a total of 16,209 shares at weighted average prices near $14 per share.

Following these transactions, the ADAR1-managed funds and accounts indirectly held 926,352 Rallybio shares. ADAR1 Capital Management and Daniel Schneeberger, each a 10% owner, may be deemed indirect beneficial owners but expressly disclaim beneficial ownership beyond any pecuniary interest.

Rallybio Corp reported insider-related buying activity by entities associated with ADAR1 Capital Management, LLC and Daniel Schneeberger. Private funds and separately managed accounts managed by ADAR1 purchased a total of 79,559 shares of Rallybio common stock in open-market transactions on May 13, 2026 and May 15, 2026.

Reported purchase prices ranged from $13.7700 to $14.0000 per share, with some trades disclosed on a weighted-average basis. The filing states these securities are owned directly by ADAR1-managed investment vehicles and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest.

Rallybio Corp reported that private investment funds and separately managed accounts managed by ADAR1 Capital Management, LLC, which may be deemed to be indirectly beneficially owned by ADAR1 and Daniel Schneeberger, completed a series of open-market purchases of common stock. On May 11–12, 2026, these accounts bought a total of 50,800 shares of Rallybio common stock in four transactions at weighted average prices around $13.83–$14.00 per share, within disclosed trading ranges from $13.75 to $14.00. Following the most recent transaction, the filing reports 830,584 shares indirectly owned. The reporting persons disclaim beneficial ownership of the securities beyond any pecuniary interest.

Rallybio Corp reported that private investment funds and separately managed accounts overseen by ADAR1 Capital Management, LLC made open‑market purchases of its common stock. Across three transactions on May 4–5, 2026, these accounts bought 155,905 shares at per‑share prices around $13.9–$14.0, increasing their indirect position to 779,784 shares. The securities may be deemed indirectly beneficially owned by ADAR1 and by Daniel Schneeberger, though each reporting person disclaims beneficial ownership beyond any pecuniary interest.

Rallybio Corp Chief Financial Officer Jonathan I. Lieber reported mixed stock transactions. On February 18, 2026, he acquired 2,500 shares of Rallybio common stock as a grant or award at $0.00 per share. On February 23, 2026, he sold 789 shares of common stock at an average price of $5.06 per share, and a footnote explains this sale was made solely to cover tax withholding obligations from the vesting of a performance stock award. Following these transactions, he directly holds 4,115 shares of Rallybio common stock.

Rallybio Corp director Martin Mackay received a stock option grant tied to his board compensation. The Form 4 shows an award of options to purchase 18,055 shares of common stock at an exercise price of $3.60 per share.

The option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $65,000 in retainer fees. It vests in 11 equal installments, each on the last day of the remaining months of calendar year 2026, meaning the award becomes exercisable gradually over that period rather than all at once.

Rallybio Corp director Ronald Hunt received an option grant to acquire 14,305 shares of common stock at $3.60 per share. The option was issued under the 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees and vests in 11 equal monthly installments over the remaining months of 2026.